Autoimmune hepatitis. Part B: diagnosis

References

• Czaja AJ. Current concepts in autoimmune hepatitis. Ann. Hepatol.4, 6–24 (2005).
   PubMedGoogle Scholar
• Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol. Dietol.51, 313–333 (2005).
   PubMedGoogle Scholar
• Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology41, 207–215 (2005).
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol.31, 929–938 (1999).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology36, 479–497 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol. Dietol.53, 43–78 (2007).
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology105, 1824–1832 (1993).
   PubMed Web of Science ®Google Scholar
• Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin. Liver Dis.6, 685–705 (2002).
   PubMedGoogle Scholar
• Cooksley WGE, Bradbear RA, Robinson W et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology6, 345–348 (1986).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig. Dis. Sci.41, 305–314 (1996).
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja AJ et al. Simplified diagnostic criteria for autoimmune hepatitis (abstract). Hepatology42, 295A (2005).
   Google Scholar
• Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology113, 664–668 (1997).
   PubMedGoogle Scholar
• Okano N, Yamamoto K, Sakaguchi K et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatology Res.25, 263–270 (2003).
   PubMed Web of Science ®Google Scholar
• Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary disease: morphologic spectrum, clinical correlations and terminology. Liver4, 105–116 (1984).
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology34, 659–665 (2001).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int.24, 322–329 (2004).
   PubMed Web of Science ®Google Scholar
• Thijs JC, Bosma A, Henzen-Logmans SC, Meuwissen SG. Postinfantile giant cell hepatitis in a patient with multiple autoimmune features. Am. J. Gastroenterol.80, 294–297 (1985).
   PubMed Web of Science ®Google Scholar
• Protzer U, Dienes HP, Bianchi L et al. Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver16, 274–282 (1996).
   PubMedGoogle Scholar
• Phillips MJ, Blendis LM, Poucell S et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N. Engl. J. Med.324, 455–460 (1991).
   PubMed Web of Science ®Google Scholar
• Fimmel CJ, Guo L, Compans RW et al. A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. Am. J. Gastroenterol.93, 1931–1937 (1998).
   PubMedGoogle Scholar
• Lau JYN, Koukoulis G, Mieli-Vergani G, Portmann BC, Williams R. Syncytial giant-cell hepatitis-a specific disease entity? J. Hepatol.15, 216–219 (1992).
   PubMedGoogle Scholar
• Roberts E, Ford-Jones EL, Phillips MJ. Ribavirin for syncytial giant cell hepatitis. Lancet341, 640–641 (1993).
   PubMedGoogle Scholar
• Durand F, Degott C, Sauvanet A et al. Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. J. Hepatol.26, 722–726 (1997).
   PubMedGoogle Scholar
• Bosch J, Coll M, Puig A et al. Autoimmune hepatitis with fatal outcome. J. Pediatr.118, 823–824 (1990).
   Google Scholar
• Maggiore G, Porta G, Bernard O et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J. Pediatr.116, 280–282 (1990).
   PubMed Web of Science ®Google Scholar
• Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J. Hepatol.21, 866–871 (1994).
   PubMedGoogle Scholar
• Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J. Hepatol.27, 578–582 (1997).
   PubMed Web of Science ®Google Scholar
• Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P. R. Health Sci. J.17, 297–300 (1998).
   PubMedGoogle Scholar
• Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin. Gastroenterol. Hepatol.2, 625–631 (2004).
   PubMed Web of Science ®Google Scholar
• Ichai P, Duclos-Vallee J-C, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Clin. Gastroenterol. Hepatol.13(7), 996–1003 (2007).
   Google Scholar
• Kerkar N, Hadzic N, Davies ET et al. De-novo autoimmune hepatitis after liver transplantation. Lancet353, 409–413 (1998).
   Google Scholar
• Heneghan MA, Portmann BC, Norris SM et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology34, 464–470 (2001).
   PubMed Web of Science ®Google Scholar
• Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am. J. Surg. Path.19, 699–708 (1995).
   PubMed Web of Science ®Google Scholar
• Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology110, 848–857 (1996).
   PubMed Web of Science ®Google Scholar
• Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J. Clin. Gastroenterol.35, 75–81 (2002).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology42, 53–62 (2005).
   PubMed Web of Science ®Google Scholar
• Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas. Ann. Med.17, 214–223 (1968).
   PubMedGoogle Scholar
• Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis.6, 799–824 (2002).
   PubMedGoogle Scholar
• DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut19, 510–513 (1978).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology95, 448–453 (1988).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Reid F et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology25, 541–547 (1997).
   PubMed Web of Science ®Google Scholar
• Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am. J. Gastroenterol.96, 3390–3394 (2001).
   PubMed Web of Science ®Google Scholar
• Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am. J. Gastroenterol.97, 2402–2407 (2002).
   PubMed Web of Science ®Google Scholar
• Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut50, 713–717 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol.13, 490–495 (1998).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Souto EO, Bittencourt PL et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J. Hepatol.37, 302–308 (2002).
   PubMed Web of Science ®Google Scholar
• D’Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int.25, 325–330 (2005).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology33, 544–553 (2001).
   PubMed Web of Science ®Google Scholar
• Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J. Hepatol.14, 325–331 (1992).
   PubMed Web of Science ®Google Scholar
• Clemente MG, Obermayer-Straub P, Meloni A et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab.82, 1353–1361 (1997).
   PubMed Web of Science ®Google Scholar
• Clemente MG, Meloni A, Obermayer-Staub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology114, 324–328 (1998).
   PubMed Web of Science ®Google Scholar
• Volta U, De Franceschi L, Molinaro N et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig. Dis. Sci.43, 2190–2195 (1998).
   PubMed Web of Science ®Google Scholar
• Kaukinen K, Halme L, Collin P et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology122, 881–888 (2002).
   PubMed Web of Science ®Google Scholar
• Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac-disease-associated autoimmune cholangitis. Am. J. Gastroenterol.97, 3196–3198 (2002).
   PubMedGoogle Scholar
• Volta U, Rodrigo L, Granito A et al. Celiac disease in autoimmune cholestatic liver disorders. Am. J. Gastroenterol.97, 2609–2613 (2002).
   PubMed Web of Science ®Google Scholar
• Green PH, Barry M, Matsutani M. Serologic tests for celiac disease. Gastroenterology124, 585–586 (2003).
   PubMed Web of Science ®Google Scholar
• Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, De Franchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand. J. Gastroenterol.38, 50–54 (2003).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem.40, 127–164 (2005).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev. Clin. Immunol.21, 33–48 (2006).
   Google Scholar
• Baeres M, Herkel J, Czaja AJ et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut51, 259–264 (2002).
   PubMed Web of Science ®Google Scholar
• Wies I, Brunner S, Henninger J, Herkel J, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet355, 1510–1515 (2000).
   PubMed Web of Science ®Google Scholar
• Costa M, Rodriques-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin. Exp. Immunol.121, 364–374 (2000).
   PubMed Web of Science ®Google Scholar
• Small-Howard A, Morozova N, Stoytcheva Z et al. Supramolecular complexes mediate selenocysteine incorporation in vivo. Mol. Cell. Biol.26, 2337–2346 (2006).
   PubMedGoogle Scholar
• Yuan J, Palioura S, Salazar JC et al. RNA-dependent conversion of phosphoserine forms selenocysteine in eukaryotes and archaea. Proc. Natl. Acad. Sci. USA103, 18923–18927 (2006).
   PubMed Web of Science ®Google Scholar
• Xu XM, Carlson BA, Mix H et al. Biosynthesis of selenocysteine on its tRNA in eukaryotes. PLoS Biol.5, e4 (2006).
   Google Scholar
• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am. J. Gastroenterol.97, 413–419 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity35, 475–483 (2002).
   PubMed Web of Science ®Google Scholar
• Ma Y,Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology35, 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet2, 954–956 (1984).
   PubMedGoogle Scholar
• Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig. Dis. Sci.41, 1733–1740 (1996).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology24, 1068–1073 (1996).
   PubMed Web of Science ®Google Scholar
• Gueguen P, Dalekos G, Nousbaum JB et al. Double reactivity against actin and α-actinin defines a severe form of autoimmune hepatitis type 1. J. Clin. Immunol.26, 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori L, Muratori P et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J. Clin. Pathol.59, 280–284 (2006).
   PubMed Web of Science ®Google Scholar
• Frenzel C, Herkel J, Luth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am. J. Gastroenterol.101, 2731–2736 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology104, 1755–1761 (1993).
   PubMedGoogle Scholar
• Vergani D, Alvarez F, Bianchi FB et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Hepatitis Group. J. Hepatol.41, 677–683 (2004).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am. J. Gastroenterol.90, 1206–1211 (1995).
   PubMed Web of Science ®Google Scholar
• Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am. J. Gastroenterol.96, 1587–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Homberg J-C, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology7, 1333–1339 (1987).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology103, 1290–1295 (1992).
   PubMed Web of Science ®Google Scholar
• Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest.88, 1370–1378 (1991).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Choudhuri K, Ma Y et al. Cytochrome P4502D6193–212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol.170, 1481–1489 (2003).
   PubMed Web of Science ®Google Scholar
• Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet1, 292–294 (1987).
   PubMed Web of Science ®Google Scholar
• Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology18, 1–9 (1993).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology105, 1522–1528 (1993).
   PubMedGoogle Scholar
• Kanzler S, Weidemann C, Gerken G et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J. Hepatol.31, 635–640 (1999).
   PubMed Web of Science ®Google Scholar
• González-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Clin. Gastroenterol. Hepatol.4, 302–310 (2001).
   Google Scholar
• Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology19, 1513–1520 (1994).
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology13, 701–706 (1991).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology25, 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology105, 1502–1507 (1993).
   PubMed Web of Science ®Google Scholar
• Montano-Loza A, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB1*03-DRB1*04 in type 1 autoimmune hepatitis. Liver Int.26, 1201–1208 (2006).
   PubMedGoogle Scholar
• Bittencourt PL, Goldberg AC, Cancado ELR et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am. J. Gastroenterol.94, 1906–1913 (1999).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am. J. Gastroenterol.92, 2197–2200 (1997).
   PubMed Web of Science ®Google Scholar
• Pando M, Larriba J, Fernandez GC et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology30, 1374–1380 (1999).
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Bittencourt PL, Mougin B et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum. Immunol.62, 165–169 (2001).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North America outside DR3 and DR4. Liver Int.26, 552–558 (2006).
   PubMedGoogle Scholar
• Czaja AJ, Carpenter HA, Moore SB. HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. Dig. Dis. Sci. (Epub ahead of print).
   Google Scholar
• Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J. Hepatol.45, 844–850 (2006).
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology (Epub ahead of print).
   Google Scholar
• Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am. J. Gastroenterol.97, 2051–2057 (2002).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology43, 532–538 (2006).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. The variant forms of autoimmune hepatitis. Ann. Intern. Med.125, 588–598 (1996).
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J. Hepatol.44, 400–406 (2006).
   PubMed Web of Science ®Google Scholar
• McNair ANB, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am. J. Gastroenterol.93, 77–784 (1998).
   Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology31, 1231–1238 (2000).
   PubMedGoogle Scholar
• Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology28, 360–365 (1998).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries (editorial). J. Hepatol.44, 251–252 (2006).
   PubMedGoogle Scholar
• Heathcote J. Variant syndromes of autoimmune hepatitis. Clin. Liver Dis.6, 669–684 (2002).
   PubMedGoogle Scholar
• Czaja AJ, Magrin S, Fabiano C et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig. Dis. Sci.40, 33–40 (1995).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology108, 157–164 (1995).
   PubMed Web of Science ®Google Scholar
• Czaja AJ. The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist? In: Cholestatic liver diseases: therapeutic options and perspectives. Falk Symposium No. 136. Leuschner U, Broome U, Stiehl A (eds). Kluwer Academic Publishers, Dordrecht, The Netherlands, 132–146 (2004).
   Google Scholar
• Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology26, 459–466 (1997).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig. Dis. Sci.40, 2098–2106 (1995).
   PubMedGoogle Scholar
• Clifford BD, Donahue D, Smith L et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology21, 613–619 (1995).
   PubMed Web of Science ®Google Scholar
• Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol.33, 99–103 (1998).
   PubMed Web of Science ®Google Scholar